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Erythropoietin (EPO), a key hormone involved in red blood cell formation has been recently acknowledged for its 
pleiotropic actions and protective role in ageing and various pathological conditions concurrent with oxidative 
stress, vascular diseases and metabolic abnormalities such as diabetes mellitus. The aim of the study was to evaluate 
the relationship between circulating erythropoietin levels and oxidative stress biomarkers, in elderly with type 2 
diabetes (T2DM). The study was carried out in 67 subjects with T2DM (69 ± 5 years; n = 37) without anemia, and 
aged-matched controls (70 ± 6 years; n = 30). EPO serum levels, erythrocyte susceptibility to lipid peroxidation 
(ESP) and total antioxidant capacity (TAC) were evaluated. Lower EPO levels (p < 0.01) and higher ESP values (p 
< 0.001) were found in T2DM group, compared to healthy subjects. EPO levels showed significant negative 
associations with ESP, both in T2DM subjects (r = –0.565; p < 0.001) and in all study population (r = –0,600; p < 
0,001; n = 67). In conclusion, we provide new data regarding the cytoprotective effect of EPO exerted at systemic 
level on erythrocyte membrane, in the particular state of impaired glucose metabolism associated with oxidative 
stress, in the elderly.
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Erythropoietin (EPO) is a key hormone involved in red blood cell formation in mammalian 
organisms. Of late years it has been widely acknowledged that erythropoietin’ s action is not 
limited to hemopoietic system, as erythropoietin involvement is being extensively evaluated 
in various pathological conditions concurrent with oxidative stress, vascular diseases, 
metabolic abnormalities or immune system dysfunction (19). Recent data of biomedical 
literature has shown that erythropoietin’s pleiotropic actions are involved in normal and 
pathological ageing (18, 20).
The Baltimore Longitudinal Study of Aging (BLSA) and the Leiden 85-plus study, have 
evidenced that EPO serum levels tend to increase with age, probably as physiological 
response required to maintain adequate red blood cell production (10). In elderly subjects 
with diabetes mellitus or hypertension, this compensatory mechanism eventually becomes 
inadequate, leading to a greater risk of developing anemia (12). Additional clinical studies 
pointed out low or inappropriately normal levels of plasma erythropoietin in diabetic patients 
with or without anemia (26, 31). These abnormalities in erythropoietin biosynthesis in patients 
with anemia and diabetes mellitus, represent an “inappropriate” response to decreasing 
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hemoglobin levels (32). Diabetic patients with anemia and decreased EPO levels may be at 
increased risk of adverse outcomes from diabetic retinopathy, nephropathy, neuropathy, and 
cardiovascular disease (24, 28).
Hyperglycemia, even during short time intervals can lead to increased reactive oxygen 
species (ROS) generation in endothelial, hepatic, beta-pancreatic cells and in erythrocytes 
(35). Peroxidation of erythrocyte membrane lipids, exposed to increased ROS impairs their 
physiological function and reduces red blood cell life-span (17).
Taking into account that besides the ability of stimulating erythrocyte production, 
erythropoietin has been extensively implicated in normal and pathological cell metabolism 
regulation through its multiple actions, and that oxidative stress induces dysfunction and 
ageing of erythrocytes, the aim of this study was to evaluate the relationship between serum 
erythropoietin and oxidative stress induced erythrocyte vulnerability in elderly subjects with 
type 2 diabetes. 
Materials and Methods
Subjects 
The study was carried out in 67 patients (34 men and 33 women) aged between 64 and 76 
years old, selected by clinical and biochemical criteria from patients hospitalized at Ana 
Aslan – National Institute of Gerontology and Geriatrics.
Two groups of study patients were selected:
1. Control group which enrolled 30 apparently healthy individuals (18 men and 12 
women, with the mean age of 69 ± 5 years).
2. Group with type 2 diabetes mellitus (T2DM) according to clinical and biochemical 
criteria of the American Diabetes Association, which included 37 patients (16 men and 21 
women, with the mean age of 70 ± 6 years), with nonfasting serum glucose levels > 126 mg/
dL, with or without oral antidiabetic medication (3). In the study T2DM subjects were 
enrolled with good or moderate glycemic control (glycated hemoglobin [HbA1c] < 8.3%), 
treated with metformin and/or sulfonylurea.
Exclusion criteria were: insulin treatment, prior history of myocardial infarction, stroke, 
as well as anemia, renal impairment, infections, neoplasic diseases, autoimmune disorders, 
rheumatoid arthritis, which might determine deficiencies in erythropoietin biosynthesis. We 
also excluded patients using iron treatment, any hormone replacement therapy, lipid-lowering 
therapy or antioxidant vitamin supplements.
The study was reviewed and approved by the Ethics Committee of the Ana Aslan – 
National Institute of Gerontology and Geriatrics (approval number 13148/13.01.2014). All 
study participants provided written informed consent prior to participation in the study.
Anthropometric and clinical characteristics were obtained from each subject after a 
complete clinical examination. Venous blood samples were collected after an overnight 12 h 
fasting period. Whole blood (EDTA as an anticoagulant) was used for erythrocytes isolation 
and ESP evaluation. The serum samples were obtained after blood centrifugation at 3500 
rpm, for 15 min at 4 oC, according to standard procedures. Serum aliquots were immediately 
stored at –70 oC until analysis for erythropoietin (EPO) and at –20 oC for total antioxidant 
status capacity (TAC) measurements. The biochemical and hematological parameters were 
determined within the same day.
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Biochemical and hematological parameters
Fasting glucose, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triglycerides (TG), uric acid, creatinine, iron, hemoglobin 
and hematocrit levels were quantified by standard methods on Konelab 20 (Finland) and 
Celltac Hematology Analyser (Nihoh, Japan). HbA1c was measured using an ion-exchange 
HPLC (Biorad Variant II).
Erythropoietin (EPO, normal range 3.22–31.9 mIU/mL serum) was measured using a 
commercially available ELISA kit (EIA-3646, DRG, USA) with intra- and inter-assay 
coefficients of variation (CV) of 4.8 and 5.1%, respectively. 
Erythrocyte susceptibility to lipid peroxidation (ESP) was determined by malonyl-
dialdehyde (MDA) formation in presence of hydrogen peroxide (H2O2) according to the 
method described by Stocks and Dormandy (29). The extent of ESP was measured by the 
thiobarbituric acid reactivity assay (TBARS) and expressed as MDA equivalent content, in 
mmol MDA/g Hb, using a calibration curve with 1,1,3,3-tetramethoxypropane.
Total antioxidant capacity (TAC) was determined using a commercially available kit 
(ImAnOx, KC 5200 Immundiagnostik AG, Germany). Antioxidants present in the serum 
sample react with a defined amount of exogenously provided hydrogen peroxide (H2O2). The 
residual H2O2 is determined by a colorimetric enzymatic method. Results are expressed as 
hydrogen-peroxide equivalents (μmol/L) as unit for the antioxidant capacity.
The biochemical and immunoenzymatic tests were performed on a ChemWell 2190 
Analyser (Awareness Technology, USA) and Lambda Bio10 Perkin-Elmer Spectrophotometer.
Statistical analysis
Results were expressed as means + standard deviation (SD). Subsequent to analysis of 
variance, the control and type 2 diabetes groups (T2DM) were compared by use of two-tail 
Student’s unpaired t-test. Differences between groups were considered statistically significant 
at values of p < 0.05. The association of serum EPO and ESP levels was analyzed by Pearson’s 
(r) partial correlations using SPSS 7.5 software. The p value of < 0.05 was considered 
statistically significant.
Results
The study was carried out in 67 elderly subjects (49% women and 51% men) with T2DM (69 
± 5 years; n = 37) without anemia, and aged-matched controls (70 ± 6 years; n = 30). There 
was no significant difference in the age or sex distribution between the study groups.
Anthropometric, clinical, hematological and biochemical parameters assessed in the 
two groups of elderly study-patients were shown in Table I. 
Hemoglobin and hematocrit levels were slightly lower (although in the normal range), 
whereas the values of fasting glucose, total cholesterol, LDL-cholesterol and triglycerides 
were significantly higher in the group of type 2 diabetes mellitus (T2DM) compared with the 
control group. Minor differences were also observed for creatinine, uric acid and serum iron 
levels. 
The oxidative stress status was evaluated at systemic level through assessments of 
erythrocytes susceptibility to lipid peroxidation (ESP) and serum total antioxidant capacity 
(TAC). The ESP was significantly higher (p < 0.001) in T2DM versus control subjects. Also, 
significantly lower TAC values were obtained in the T2DM group compared to the control 
(Table II).
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Table I. Clinical, hematological and biochemical characteristics in control  








mean ± SD mean ± SD
Age (years) 69 ± 5 70 ± 6 NS
Sex (male/female) 18/12 16/21
Blood pressure (mmHg) 129/80 ± 11/8 147/86 ± 21/15 NS
BMI (kg/m2) 23.2 ± 1.5 24.3 ± 3.2 NS
Hemoglobin (g/dL) 14.6 ± 0.8 14.1 + 1.1 < 0.05
Hematocrit (%) 42 ± 2 40 ± 5 < 0.05
Fasting glucose (mg/dL) 89 ± 3 142 ± 17 < 0.001
HbA1c (%) 5.5 ± 0.3 7.4 ± 0.8 < 0.001
Total cholesterol (mg/dL) 198 ± 19 221 ± 37 < 0.01
Triglycerides (mg/dL) 101 ± 30 156 ± 57 < 0.001
LDL-C (mg/dL) 118 ± 24 143 ± 15 < 0.001
HDL-C (mg/dL) 59 ± 11 50 ± 15 < 0.01
Iron (μg/dL) 75 ± 13 72 ± 17 NS
Uric acid (mg/dL) 3.32 ± 1.8 4.42 ± 2.1 < 0.05
Creatinine (mg/dL) 0.92 ± 0.1 1.17 ± 0.7 < 0.05
SD = standard deviation; p values represent statistical significance when comparing against the Control group;  
NS = non-significant; BMI = Body Mass Index; HbA1c = glycated hemoglobin; LDL-C = low-density lipoprotein 
cholesterol; HDL-C = high-density lipoprotein cholesterol
Table II. Serum erythropoietin (EPO) levels, erythrocyte susceptibility to lipid peroxidation (ESP)  








mean ± SD mean ± SD
EPO (ng/mL) 22.6 ± 6.8 17.3 ± 5.8 < 0.01
ESP (mmole/g Hb) 362 ± 55 537 ± 140 < 0.001
TAC (μmol/L) 223 ± 142 331 ± 162  0.01
SD = standard deviation; p values represent statistical significance when comparing against the Control group
In elderly subjects with type T2DM, significantly lower serum erythropoietin levels 
were found compared with the healthy group (p < 0.01) (Table II). 
The study of interrelations between circulating serum erythropoietin concentrations and 
erythrocyte susceptibility to peroxidation showed significant negative associations both in 
T2DM subjects (r = –0.565; p < 0.001; n = 37) and all study population (r= –0,600; p < 0,001; 
n = 67) (Figs 1 and 2). A significant negative correlation was observed even in the control 
group (r = –0.590; p < 0.001; n = 30) (data not shown).
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Fig. 1. Correlation between serum erythropoietin (EPO) levels and erythrocyte susceptibility  
to lipid peroxidation (ESP) in type 2 diabetes mellitus elderly subjects (n = 37)
Fig. 2. Correlation between serum erythropoietin (EPO) levels and erythrocyte susceptibility  
to lipid peroxidation (ESP) for all study subjects (n = 67)
Discussion
Erythropoietin is among the first hormonal factors discovered in humans, involved in both 
erythropoiesis and various cytoprotective pathways. In basic experimental research and 
clinical studies, erythropoietin has been strongly associated with modulation of cellular 
metabolism (19, 20). Diabetes mellitus, a major public health problem, comes also as main 
evidence when cellular dysfunction related to cell metabolism is under scrutiny (21). 
Furthermore, metabolic disturbances and oxidative stress appear to be strongly related in the 
etiopathogeny of type 2 diabetes.
Several studies evidenced that oxidative status was improved by EPO treatment of 
anemia (2, 11, 25). EPO therapy may exert its antioxidant effect, by modulating the action 
of erythrocyte antioxidant enzymes such as superoxide dismutase and glutathione 
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peroxidase (25). Also, recent results showed that EPO treatment increased the GSH levels in 
both erythrocytes and platelets, in β-thalassemic patients (2). However, the relationships 
between EPO and erythrocyte oxidative stress in elderly subjects with diabetes have been 
less explored. 
Normal erythrocyte function depends on integrity of the erythrocyte membrane, which 
is a target for numerous toxic prooxidant factors, including chronic hyperglycemia (22, 30). 
Erythrocyte membrane is among the main targets for oxygen radicals or peroxides as it 
contains both polyunsaturated fatty acids (PUFA), which are the most susceptible substrate 
for lipid peroxidation as well as prooxidant catalysts such as Fe2+ and hemoproteins (23, 33). 
Hence, the erythrocyte susceptibility to peroxidation represents an informative biomarker on 
red blood cell mechanisms and capability of antioxidant protection against free radicals. 
Therefore, in this study we aimed to investigate the correlation between circulating EPO 
levels and systemic oxidative stress biomarkers, in elderly with type 2 diabetes (T2DM). In 
view of this purpose, we evaluated the erythrocytes susceptibility to lipid peroxidation (ESP) 
and serum total antioxidant capacity (TAC).
Results showed that elderly T2DM subjects had a decreased antioxidant defense, in both 
serum samples and erythrocytes, compared to healthy subjects, which is in accordance with 
previous studies (14, 15). Also, lower levels of EPO were found in subjects with impaired 
glucose metabolism, compared with age-matched controls. The main finding of our study 
showed that erythropoietin levels correlated inversely and significantly with oxidative stress 
exerted at erythrocyte level (ESP), even though hemoglobin, the circulating erythrocyte mass 
and serum iron levels were comparable. Also, lower levels of EPO in T2DM group were 
associated with a significant decrease in serum antioxidant capacity (TAC). Subsequently to 
establishing these associations, the following questions could be raised: to what extent 
diabetes determine a decrease in EPO biosynthesis and to what extent diabetes per se can 
initiate oxidative damage of erythrocyte membrane? And not in the least, which might be the 
mechanisms of the antioxidant EPO protection expressed at erythrocyte level?
Diabetes-related chronic hyperglycemia can lead to a hypoxic environment in the renal 
interstitium, which results in impaired production of erythropoietin by the peritubular 
fibroblasts and in diabetes nephropathy, subsequent anemia (28). The distinction between 
T2DM patients with anemia and those with diabetic nephropathy in whom anemia has not 
been evidenced, lies in a defect of “anemia-sensing” mechanisms particular to these later 
mentioned patients, and that may contribute to EPO deficiency and explain low EPO levels 
(9). In ageing, the decline in the capacity to produce EPO could be due to a mechanism 
distinct from impaired renal excretory function. Certain ageing-associated disorders such as 
diabetes mellitus and hypertension, could accentuate the impairment in EPO secretion (12).
Due to their physiological roles, erythrocytes are continuously exposed to oxidative 
stress. Results obtained confirm observations of literature regarding the damaging effects of 
hyperglycemia mediated or stimulated by oxygen species. Mechanisms could be the 
following: 1) glucose oxidation pathways generate oxygen free radicals; 2) hyperglycemia 
deteriorates antioxidant capacity, and 3) mitochondria-derived reactive oxygen species is 
generated in hyperglycemic states (6, 19, 21).
Moreover, in kidney cells hyperglycemia increases mitochondrial ROS production 
which alters the transcription factors involved in the control of hypoxia and oxidative stress 
response in relation with the renal hypoxia-inducible factor (HIF) pathway, involved in 
erythropoiesis (19). Research has extended to the effects of EPO in regulating oxidative 
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metabolism and mitochondrial function, the interactions between EPO and important energy 
regulation factors, and the protective role of EPO from stresses that are related to metabolism, 
which have been recently reviewed (34, 35).
EPO may exert its antioxidative effects directly by involvement in intracellular 
mechanisms such as up-regulation of hem oxygenase-1 expression, superoxide dismutase, 
catalase and glutathione peroxidase activities, and by inhibiting reactive oxygen species 
generation. Recent studies found the recombinant form of EPO (rHuEPO) to be a potent 
scavenger of HO˙with the capacity to inhibit Fenton chemistry through catalytic iron 
chelation. Its ability to scavenge peroxyl (ROO˙) radicals, evaluated in vitro, was also 
superior compared to other antioxidants (5). The indirect antioxidant EPO action could be 
achieved through iron depletion and thus limitation of iron-dependent oxidative injury, and 
by increasing new red blood cells (RBC) loaded with a significant amount of antioxidants 
(1, 2, 11, 16). 
Previous studies pointed out also an inverse association between hemoglobin 
concentrations and erythrocyte membrane MDA (13). In our study population hemoglobin 
and serum iron concentrations were comparable, and within normal ranges, therefore we 
could suggest that mainly erythropoietin and not hemoglobin, nor iron determined the 
changes in oxidative stress parameters.
Recent in vitro and in vivo studies underline the antioxidative EPO effect in various 
cell systems: erythrocytes, neurons, microglia, astrocytes, cerebral endothelial cells, 
cardiomyocytes, retinal cell (2, 11, 16, 20). In in vitro studies on blood vessel cells exposed 
to increased glucose concentrations a strong cyto-protective EPO effect was noticed (8). 
Similarly to insulin, also for EPO protective effects were demonstrated, subsequent to its 
administration to diabetic and non-diabetic patients, with resistant, severe congestive heart 
failure (27). EPO administration can significantly improve survival of endothelial cells and 
moreover, EPO can block DNA degradation in the course of apoptosis of endothelial cells 
under hyperglycemia conditions, similarly to other experimental models of oxidative stress 
in cultured cardiac and endothelial cells (4). A recent study which investigated the time-
dependent effects of EPO therapy on oxidative stress parameters of hemodialysis patients 
showed that long term administration of EPO attenuated the lipid peroxidation process and 
restored the levels of antioxidants (11). New in vivo research showed potent protective effects 
of EPO against diabetes development by direct effects of EPO on β-cells by increasing β-cell 
mass through anti-apoptotic, proliferative and angiogenic mechanisms (7).
The strong inverse association between EPO levels and ESP pointed out in our study, in 
T2DM, could reflect the diminished RBC membrane cytoprotection by reducing the strength 
of total antioxidant potential at systemic level. Further in vitro experimental models and in 
vivo studies are needed to demonstrate the precise mechanisms.
The limitations of this study could be the small population sample and the global 
assessment of oxidative stress damage exerted on erythrocytes (ESP) without specific 
evaluations of biomarkers of erythrocyte antioxidant defense, such as superoxide dismutase, 
glutathione, glutathione peroxidase and catalase. As oxidative stress in diabetes is suggested 
to be associated also with chronic low-grade inflammation, another limitation of the study is 
the lack in the assessment of sensitive inflammatory markers (such as hsCRP, IL-6, TNF-α), 
therefore we could not point out relationships between decreased EPO serum levels, oxidative 
stress markers and inflammation.
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The present study provides new data regarding the protective effect of EPO expressed at 
systemic level, and the relationships between circulating EPO levels, impaired glucose 
metabolism and erythrocyte susceptibility to oxidative damage. Since administration of 
antioxidants in the course of hyperglycemia can block free radical generation and reduce 
oxidative stress, EPO could offer an alternative therapy appealing in view of maintenance of 
normal cell metabolism and appropriate membrane potential. Hence, inhibition of oxidative 
damage of cell components could represent a new modality of EPO therapeutic intervention 
in diabetes. In this sense, in the future both glucose lowering therapy as well as judicious 
early supplementation with erythropoietin could lead to delay or block the development of 
anemia and vascular complications in elderly diabetic patients.
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